Heart Block, Pacemaker DDD
Conditions
Keywords
left bundle branch pacing
Brief summary
High burden right ventricular (RV) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle branch pacing (LBBP) has emerged as a potential alternative pacing mechanism that may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical conduction.
Detailed description
We hypothesize that in patients with high degree AV block with anticipated ventricular pacing \>90%, and an EF \>35% patients undergoing LBBP will demonstrate a significantly lower number of the primary composite endpoint of cardiovascular death, heart failure events, and change in LVESVi as compared to standard RV pacing. Echos will be performed at baseline, 12, 24, and 36 months. NTproBNPs are performed at baseline and follow-up. There will be a core echo lab, and blinded adjudication of ECGs and events.
Interventions
Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
Active fixation lead (standard)
Sponsors
McGill University Health Centre/Research Institute of the McGill University Health Centre
Heart and Stroke Foundation of Canada
Canadian Institutes of Health Research (CIHR)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Blinded outcome adjudication
Intervention model description
Prospective open-label randomized controlled trial (1:1) with blinded outcome adjudication
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Patients with an ejection fraction of \>35% 3. Patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated RV pacing is \>90% including: 1. Third degree AV block 2. Symptomatic or asymptomatic second-degree AV block 3. First degree AV block ≥ 280ms with a narrow QRS, or ≥ 240ms with an intraventricular delay (QRS duration ≥120ms) 4. Echocardiogram within the last 3 months, with ability to have DICOM images
Exclusion criteria
1. Indication for an implantable cardioverter defibrillator 2. Presence of a mechanical tricuspid valve 3. Any prior attempt at implantation of an ICD, CRT, HBP, or LBBP 4. Lack of capacity to consent 5. Other serious medical condition with life expectancy of \<2 years 6. Pregnancy 7. Patients in whom the conduction system abnormality is expected to be transient or recover over time 8. Patients with permanent atrial fibrillation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to cardiovascular death | 36 months | Clinical |
| Time to first heart failure event | 36 months | Defined as: (i) Emergency department (ED) visits or hospitalization for HF (requiring signs and symptoms consistent with congestive heart failure (CHF) that is responsive to oral or parenteral medications); (ii) intensification of therapy (intravenous diuretic therapy on an outpatient basis); or (iii) indication for device upgrade to CRT due to deteriorating LV function defined as an absolute decline in LVEF ≥ 10% from baseline and an LVEF ≤ 40% |
| Worsening LV end systolic volume index by 2 years | 24 months | Defined as a 15% increase from baseline each year up to the two-year echo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular mortality | 24 months | CV-related |
| New visit for Heart Failure | 24 months | Heart failure visit is defined as: i) Emergency department visit or hospitalization for signs and symptoms of HF that is responsive to oral or intravenous diuretics ii) intensification of therapy defined as outpatient intravenous diuretic therapy, and iii) device upgrade to cardiac resynchronization therapy. |
| Total mortality | 24 months | Total mortality |
| Change in left ventricular ejection fraction | 24 months | Echo parameter, change from baseline to 24 months |
| Change in NTproBNP level | 24 months | From baseline to 24 months |
| Atrial fibrillation progression | 24 months | Atrial fibrillation burden as noted on pacemaker |
| Development of new tricuspid regurgitation | 24 months | More than mild TR from baseline |
| Presence of Mitral regurgitation | 24 months | Progression/Development from baseline |
| Change in Lead parameter | 24 months | stability of impedance, sensing, thresholds |
| Quality of Life Improvement | Evaluated at 1, 12, and 24 months, measure as compared to baseline | Health related quality of life score: Short Form 12 |
| Safety of procedure and long-term safety | 24 months | Procedural and long-term safety of left bundle pacing |
Countries
Canada
Contacts
CONTACTJacqueline Joza, MD MSc
CONTACTFiorella Rafti, PhD
Outcome results
None listed